Clinical and Translational Theranostics

• You have access

  In Memoriam: Dirk J. Kwekkeboom (1958–2017)

  Lisa Bodei

  Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 7A;
• You have access

  Theranostic Concepts: More Than Just a Fashion Trend—Introduction and Overview

  Ken Herrmann, Steven M. Larson and Wolfgang A. Weber

  Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 1S-2S; DOI: https://doi.org/10.2967/jnumed.117.199570
• You have access

  Clinical History of the Theranostic Radionuclide Approach to Neuroendocrine Tumors and Other Types of Cancer: Historical Review Based on an Interview of Eric P. Krenning by Rachel Levine

  Rachel Levine and Eric P. Krenning

  Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 3S-9S; DOI: https://doi.org/10.2967/jnumed.116.186502
• You have access

  Approaches to Multireceptor Targeting: Hybrid Radioligands, Radioligand Cocktails, and Sequential Radioligand Applications

  Jean Claude Reubi and Helmut R. Maecke

  Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 10S-16S; DOI: https://doi.org/10.2967/jnumed.116.186882
• You have access

  Glu-Ureido–Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers

  Klaus Kopka, Martina Benešová, Cyril Bařinka, Uwe Haberkorn and John Babich

  Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 17S-26S; DOI: https://doi.org/10.2967/jnumed.116.186775
• You have access

  Identification of Ligands and Translation to Clinical Applications

  Uwe Haberkorn, Walter Mier, Klaus Kopka, Christel Herold-Mende, Annette Altmann and John Babich

  Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 27S-33S; DOI: https://doi.org/10.2967/jnumed.116.186791
• You have access

  Iodine Symporter Targeting with ¹²⁴I/¹³¹I Theranostics

  James Nagarajah, Marcel Janssen, Philipp Hetkamp and Walter Jentzen

  Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 34S-38S; DOI: https://doi.org/10.2967/jnumed.116.186866
• You have access

  Norepinephrine Transporter as a Target for Imaging and Therapy

  Neeta Pandit-Taskar and Shakeel Modak

  Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 39S-53S; DOI: https://doi.org/10.2967/jnumed.116.186833
• You have access

  Somatostatin Receptor 2–Targeting Compounds

  Daan A. Smit Duijzentkunst, Dik J. Kwekkeboom and Lisa Bodei

  Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 54S-60S; DOI: https://doi.org/10.2967/jnumed.117.191015
• You have access

  Somatostatin Receptor Antagonists for Imaging and Therapy

  Melpomeni Fani, Guillaume P. Nicolas and Damian Wild

  Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 61S-66S; DOI: https://doi.org/10.2967/jnumed.116.186783
• You have access

  Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy

  Matthias Eiber, Wolfgang P. Fendler, Steven P. Rowe, Jeremie Calais, Michael S. Hofman, Tobias Maurer, Sarah M. Schwarzenboeck, Clemens Kratowchil, Ken Herrmann and Frederik L. Giesel

  Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 67S-76S; DOI: https://doi.org/10.2967/jnumed.116.186767
• You have access

  CXCR4 Ligands: The Next Big Hit?

  Annemiek M.E. Walenkamp, Constantin Lapa, Ken Herrmann and Hans-Jürgen Wester

  Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 77S-82S; DOI: https://doi.org/10.2967/jnumed.116.186874
• You have access

  Theranostics Using Antibodies and Antibody-Related Therapeutics

  Kirsten L. Moek, Danique Giesen, Iris C. Kok, Derk Jan A. de Groot, Mathilde Jalving, Rudolf S.N. Fehrmann, Marjolijn N. Lub-de Hooge, Adrienne H. Brouwers and Elisabeth G.E. de Vries

  Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 83S-90S; DOI: https://doi.org/10.2967/jnumed.116.186940
• You have access

  Therapeutic Radiometals Beyond ¹⁷⁷Lu and ⁹⁰Y: Production and Application of Promising α-Particle, β⁻-Particle, and Auger Electron Emitters

  Cristina Müller, Nicholas P. van der Meulen, Martina Benešová and Roger Schibli

  Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 91S-96S; DOI: https://doi.org/10.2967/jnumed.116.186825
• You have access

  Individualized Dosimetry for Theranostics: Necessary, Nice to Have, or Counterproductive?

  Uta Eberlein, Marta Cremonesi and Michael Lassmann

  Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 97S-103S; DOI: https://doi.org/10.2967/jnumed.116.186841
• You have access

  Radioembolization of Colorectal Liver Metastases: Indications, Technique, and Outcomes

  F. Edward Boas, Lisa Bodei and Constantinos T. Sofocleous

  Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 104S-111S; DOI: https://doi.org/10.2967/jnumed.116.187229